Currently out of the existing stock ratings of Jotin Marango, 10 are a BUY (90.91%), 1 are a HOLD (9.09%).

Jotin Marango

Work Performance Price Targets & Ratings Chart

Analyst Jotin Marango, carries an average stock price target met ratio of 33.33% that have a potential upside of 64.35% achieved within 118 days. Previously, Jotin Marango worked at ROTH.

Jotin Marango’s has documented 24 price targets and ratings displayed on 7 stocks. The coverage was on Healthcare, Technology sectors.

Most recent stock forecast was given on VSTM, Verastem at 14-May-2019.

Wall Street Analyst Jotin Marango

Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for ARQL (ARQULE) at 2/22/2018. The price target of $5 was fulfilled within 92 days with a profit of $3.21 (179.33%) receiving and performance score of 19.49.

Average potential price target upside

AIMT Aimmune Therapeutics VSTM Verastem ARQL ArQule EPZM Epizyme KALV Kalvista Pharmaceuticals AI C3 Ai SVRA Savara

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 19-Dec-2019

$18

5 years 7 months 7 days ago
(01-Sep-2020)

3/3 (100%)

$3.19 (21.54%)

78

Buy Since 03-Jun-2019

$60

5 years 7 months 8 days ago
(31-Aug-2020)

0/19 (0%)

$41.31 (221.03%)

Buy Since 14-Jun-2016

$34.5

$0.01 (0.03%)

$66

5 years 7 months 8 days ago
(31-Aug-2020)

1/9 (11.11%)

$0.28 (0.82%)

39

Hold Since 04-Feb-2020

$34.5

$0.01 (0.03%)

5 years 7 months 8 days ago
(31-Aug-2020)

5/5 (100%)

$0.28 (0.82%)

138

Buy Since 17-Nov-2015

$35

$0.51 (1.48%)

5 years 7 months 8 days ago
(31-Aug-2020)

5/14 (35.71%)

$0.78 (2.28%)

488

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Jotin Marango?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?